The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 05, 2016
Filed:
Sep. 19, 2014
Centro DE Ingenieria Genetica Y Biotecnologia, Ciudad de la Habana, CU;
Silvio Ernesto Perea Rodríguez, Ciudad de la Habana, CU;
Yasser Perera Negrín, La Habana, CU;
Arielis Rodríguez Ulloa, La Habana, CU;
Jeovanis Gil Valdés, Ciudad de la Habana, CU;
Yassel Ramos Gómez, Ciudad de la Habana, CU;
Lila Rosa Castellanos Serra, Cuidad de la Habana, CU;
Lázaro Hiram Betancourt Núñez, Ciudad de la Habana, CU;
Aniel Sánchez Puente, Ciudad de la Habana, CU;
Jorge Fernández de Cossio Dorta Duque, Ciudad de la Habana, CU;
Boris Ernesto Acevedo Castro, Ciudad de la Habana, CU;
Luis Javier González López, Ciudad de la Habana, CU;
Vladimir Besada Pérez, Ciudad de la Habana, CU;
Daniel Fernando Alonso, Buenos Aires, AR;
Daniel Eduardo Gomez, Buenos Aires, AR;
BIOREC S.A., Montevideo, UY;
CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA, Ciudad de la Habana, CU;
Abstract
This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemothearapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomycin C, imatinib, iressa and velcade (bortezomib). The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy. Furthermore, the sequential administration of this pharmaceutical combination through the pretreatment with the P15 peptide leads to the chemo sensibilization of refractory tumors to the anticancer therapeutics.